+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07623798

Comparing IBI3003 to Investigators Choice Treatments in Relapsed or Refractory Multiple Myeloma Patients

Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2026-09-17

255

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of IBI3003 compared to the investigators choice of treatment regimens DPd, PVd, or SVd in participants with relapsed or refractory multiple myeloma who have received 1 to 4 prior therapies and been exposed to three classes of drugs including proteasome inhibitors, immunomodulators, and anti-CD38 monoclonal antibodies. This phase III randomized controlled trial plans to enroll about 255 participants, with a 21 randomization between IBI3003 and the investigators choice regimen. Participants in the experimental group will receive IBI3003 dosed according to body weight until death, disease progression, starting a new anti-tumor therapy, withdrawal of consent, or other reasons for stopping treatment. Those in the control group will receive one of the three regimens DPd, PVd, or SVd, with specific dosing schedules for each drug in the regimens. Participants who stop IBI3003 treatment may enter an observation period and can restart treatment if certain criteria are met, based on discussions with their doctor and preference. Throughout the study, participants will have regular assessments to monitor disease status and safety. The main outcome measured is progression-free survival over up to 24 months after the first dose. Secondary outcomes include various rates of response and minimal residual disease negativity, duration and timing of responses, overall survival, and safety events. Quality of life and symptom assessments will also be conducted during this period. The study is expected to last several years with ongoing monitoring until study completion.

CONDITIONS

Brief Title

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

Research Team

H

Haiyan Zhu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here